Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspectives about the impact of nonhealing chronic wounds on daily life, patient views on treatment approaches, factors to consider when selecting a treatment, and what they consider when determining whether to participate in a clinical trial.

Abstract as published in the Federal Register.

The comment window is still open until October 26, 2026. This is the point where industry shapes the final rule — submit comments through the Federal Register document below.

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.